A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Selpercatinib (Primary) ; Cabozantinib; Vandetanib
- Indications Medullary thyroid cancer; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms LIBRETTO-531
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Loxo Oncology
Most Recent Events
- 04 Feb 2025 The protocol has been amended change in time frame.
- 04 Feb 2025 Planned End Date changed from 28 Feb 2026 to 1 Feb 2026.
- 23 May 2024 According to an Eli Lilly and Company media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 - June 4 in Chicago.